Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com

Syros Pharmaceuticals (NASDAQ:SYRS) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday.

Several other equities research analysts also recently weighed in on SYRS. Piper Sandler reissued an “overweight” rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Monday, April 1st.

Syros Pharmaceuticals Trading Down 8.1 %

Shares of SYRS traded down $0.45 during midday trading on Wednesday, hitting $5.11. The stock had a trading volume of 125,722 shares, compared to its average volume of 218,592. Syros Pharmaceuticals has a 1 year low of $2.09 and a 1 year high of $8.17. The firm has a market cap of $136.59 million, a PE ratio of -0.89 and a beta of 1.74. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.95 and a quick ratio of 3.95. The stock’s 50 day moving average is $6.34 and its 200 day moving average is $5.19.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Bain Capital Life Sciences Investors LLC increased its stake in Syros Pharmaceuticals by 29.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company’s stock worth $21,421,000 after buying an additional 625,114 shares during the period. Avidity Partners Management LP increased its stake in Syros Pharmaceuticals by 5.8% in the 4th quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company’s stock worth $13,037,000 after buying an additional 92,396 shares during the period. Blue Owl Capital Holdings LP purchased a new position in Syros Pharmaceuticals in the 4th quarter worth about $11,632,000. Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals during the 4th quarter worth about $11,465,000. Finally, CHI Advisors LLC grew its holdings in Syros Pharmaceuticals by 69.3% during the 3rd quarter. CHI Advisors LLC now owns 1,299,359 shares of the company’s stock worth $5,119,000 after acquiring an additional 531,914 shares in the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.